Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares Outstanding
Ratios

Enanta Pharmaceuticals (ENTA) Receivables Refunds (2020 - 2025)

Historic Receivables Refunds for Enanta Pharmaceuticals (ENTA) over the last 6 years, with Q2 2025 value amounting to $24000.0.

  • Enanta Pharmaceuticals' Receivables Refunds fell 9992.61% to $24000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $24000.0, marking a year-over-year decrease of 9992.61%. This contributed to the annual value of $32.0 million for FY2024, which is 320.93% up from last year.
  • As of Q2 2025, Enanta Pharmaceuticals' Receivables Refunds stood at $24000.0, which was down 9992.61% from $33.8 million recorded in Q1 2025.
  • Enanta Pharmaceuticals' Receivables Refunds' 5-year high stood at $37.3 million during Q3 2021, with a 5-year trough of $24000.0 in Q2 2025.
  • For the 5-year period, Enanta Pharmaceuticals' Receivables Refunds averaged around $28.9 million, with its median value being $30.6 million (2021).
  • In the last 5 years, Enanta Pharmaceuticals' Receivables Refunds surged by 18567.59% in 2021 and then tumbled by 9992.61% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Receivables Refunds (Quarter) stood at $28.8 million in 2021, then decreased by 0.17% to $28.7 million in 2022, then grew by 10.56% to $31.7 million in 2023, then grew by 2.24% to $32.4 million in 2024, then tumbled by 99.93% to $24000.0 in 2025.
  • Its Receivables Refunds was $24000.0 in Q2 2025, compared to $33.8 million in Q1 2025 and $32.4 million in Q4 2024.